Show simple item record

dc.contributor.authorLöding, Sebastian
dc.contributor.authorAndersson, Ulrika
dc.contributor.authorKaaks, Rudolf
dc.contributor.authorSchulze, Matthias B.
dc.contributor.authorPala, Valeria
dc.contributor.authorUrbarova, Ilona Halva
dc.contributor.authorAmiano, Pilar
dc.contributor.authorColorado-Yohar, Sandra M.
dc.contributor.authorGuevara, Marcela
dc.contributor.authorHeath, Alicia K.
dc.contributor.authorChatziioannou, Anastasia Chrysovalantou
dc.contributor.authorJohansson, Mattias
dc.contributor.authorNyberg, Lars Erik
dc.contributor.authorAntti, Henrik
dc.contributor.authorBjörkblom, Benny
dc.contributor.authorMelin, Beatrice
dc.date.accessioned2023-11-17T11:46:10Z
dc.date.available2023-11-17T11:46:10Z
dc.date.issued2023-08-31
dc.description.abstractGenetic and metabolic changes in tissue and blood are reported to occur several years before glioma diagnosis. Since gliomas are currently detected late, a liquid biopsy for early detection could affect the quality of life and prognosis of patients. Here, we present a nested case-control study of 550 prediagnostic glioma cases and 550 healthy controls from the Northern Sweden Health and Disease study (NSHDS) and the European Prospective Investigation into Cancer and Nutrition (EPIC) study. We identified 93 significantly altered metabolites related to glioma development up to 8 years before diagnosis. Out of these metabolites, a panel of 20 selected metabolites showed strong disease correlation and a consistent progression pattern toward diagnosis in both the NSHDS and EPIC cohorts, and they separated future cases from controls independently of biological sex. The blood metabolite panel also successfully separated both lower-grade glioma and glioblastoma cases from controls, up to 8 years before diagnosis in patients within the NSHDS cohort and up to 2 years before diagnosis in EPIC. Pathway enrichment analysis detected metabolites related to the TCA cycle, Warburg effect, gluconeogenesis, and cysteine, pyruvate, and tyrosine metabolism as the most affected.en_US
dc.identifier.citationLöding, Andersson, Kaaks, Schulze, Pala, Urbarova, Amiano, Colorado-Yohar, Guevara, Heath, Chatziioannou, Johansson, Nyberg, Antti, Björkblom, Melin. Altered plasma metabolite levels can be detected years before a glioma diagnosis. JCI Insight. 2023;8(19)en_US
dc.identifier.cristinIDFRIDAID 2193990
dc.identifier.doi10.1172/jci.insight.171225
dc.identifier.issn2379-3708
dc.identifier.urihttps://hdl.handle.net/10037/31802
dc.language.isoengen_US
dc.publisherAmerican Society for Clinical Investigationen_US
dc.relation.journalJCI Insight
dc.rights.accessRightsopenAccessen_US
dc.rights.holderCopyright 2023 The Author(s)en_US
dc.rights.urihttps://creativecommons.org/licenses/by/4.0en_US
dc.rightsAttribution 4.0 International (CC BY 4.0)en_US
dc.titleAltered plasma metabolite levels can be detected years before a glioma diagnosisen_US
dc.type.versionpublishedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


File(s) in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

Attribution 4.0 International (CC BY 4.0)
Except where otherwise noted, this item's license is described as Attribution 4.0 International (CC BY 4.0)